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Abstract

Common variable immunodeﬁciency (CVID) is deﬁned by low levels of IgG and IgA, but perturbations in T cells are also commonly
found. However, there is limited information on gd T cells in CVID patients. Newly diagnosed CVID patients (n = 15) were enrolled
before and after intravenous IgG (IVIg) replacement therapy. Cryopreserved peripheral blood mononuclear cells were then used to
study gd T cells and CVID patients were compared to healthy controls (n = 22). The frequency and absolute count of Vd1 gd T cells
was found to be increased in CVID (median 0.60% vs 2.64%, P <0.01 and 7.5 vs 39, P <0.01 respectively), while they were
decreased for Vd2 gd T cells (median, 2.36% vs 0.74%, P <0.01 and 37.8 vs 13.9, P <0.01 respectively) resulting in an inversion of
the Vd1 to Vd2 ratio (0.24 vs 1.4, P <0.001). Markers of immune activation were elevated on all subsets of gd T cells, and HLA-DR
expression was associated with an expansion of Vd1 gd T cells (r = 0.73, P = 0.003). Elevated PD-1 expression was found only on Vd2
gd T cells (median 1.15% vs 3.08%, P <0.001) and was associated with the decrease of Vd2 gd T cells (r = 0.67, P = 0.007). IVIg had
no effect on the frequency of Vd1 and Vd2 gd T cells or HLA-DR expression, but alleviated CD38 expression on Vd1 gd T cells (median
MFI 965 vs 736, P <0.05). These ﬁndings suggest that immunological perturbations of gd T cells are a general feature associated with
CVID and are only partially reversed by IVIg therapy.
Abbreviations: CVID = common variable immunod, DN = double negative, IVIg = intravenous immunoglobulin, PD-1 =
Programmed Death 1.
Keywords: CVID, gamma delta T cells, immune activation, IVIg, PD-1, Vd1, Vd2

1. Introduction
Common variable immunodeﬁciency (CVID) is characterized by
low levels of IgG and IgA and/or IgM (2 standard deviations
below the normal level) and by an impaired antibody response to
vaccination.[1] While some genetic mutations causing CVID have
been identiﬁed, it is thought to be a polygenic disease with
multiple susceptibility loci involved.[2] The poor antibody
response in CVID patients results in recurrent infections of the
respiratory and gastrointestinal tracts. CVID patients also have
an increased incidence of some forms of cancer and autoimmunity,[3,4] probably due to the chronic state of immune activation
and loss of key regulatory cells.[5–8] Treatment for CVID consists
of IgG replacement that can be given subcutaneous or
intravenously (IVIg). Replacement therapy signiﬁcantly reduces
the number of infections[9] and corrects some immune abnormalities,[10] while other perturbations are only partially restored
or unchanged.[6]
In humans, gd T cells represent between 0.5% and 16% of T
cells in the blood with an average of approximately 4%.[11] The
major subsets are designated Vd1 and Vd2, the latter being the
most abundant. Similar to ab T cells, gd T cells develop in the
thymus and undergo gene rearrangement, but they are not
subjected to positive selection.[12] They can produce similar
cytokines to conventional ab T cells, including IL-17,[13] and can
also have cytotoxic functions. Following infection, gd T cells are
activated earlier than ab T cells and are involved in the initiation
of the inﬂammatory response.[11] The antigens recognized by gd
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plates in the dark. Samples were then washed and ﬁxed using
Cytoﬁx/Cytoperm (BD Biosciences) before ﬂow cytometry data
acquisition. mAbs used in ﬂow cytometry; CD3 AF700 (clone
UCHT1), CD4 PE-CF594 (clone RPA-T4), CD8 BV711 (clone
RPA-T8), CD38 APC-H7 (clone HB7), CD161 BV421
(clone DX12), HLA-DR APC (clone L243), TCR gd BV650
(clone B1), and PD-1 PE-Cy7 (clone EH12.1) were all from BD
Biosciences, TCR Vd1 FITC (clone TS8.2) was from Abcam
(Cambridge, MA), and TCR Vd2 PE (clone B6) was from
Biolegend (San Diego, CA). Live/dead aqua ﬁxable cell stain was
from Life Technologies (Eugene, OR). All antibodies were used
together in 1 panel. A minimum number of 200 events were
recorded for all subsets of gd T cells. Data were acquired on a BD
LSRFortessa instrument (BD Biosciences) and analyzed using
FlowJo Version 9.8.5 software (TreeStar, Ashland, OR).

T cells are very diverse and include phosphoantigens, peptides,
and glycolipids.[11,14] The gd TCR can also recognize stressinduced ligands. For instance, a Vg4Vd5 T cell clone has been
shown to recognize EPCR expression on tumor cell and CMVinfected cells.[15]
HIV infection leads to a profound perturbation of the gd T
cells population,[16] characterized by an early expansion of the
Vd1 T cells, while Vd2 T cells are greatly reduced in number.[17]
Vd2 T cells from HIV patients were also found to have a lower
capacity to respond to phosphoantigens.[18] The expansion of
Vd1 T cells has been associated with increased microbial
translocation,[19] now recognized as a major contributor of
chronic immune activation in HIV infection.[20] CVID patients
share several immunological features with HIV patients, namely
CD4+ and CD8+ T cell activation, loss of iNKT cells and of
regulatory T cells.[5,6] In contrast to CVID, HIV is characterized
by hypergammaglobulinemia, but HIV disease progression is
characterized by loss of memory B cell subsets and impaired
antibody response to vaccination.[21,22] Increased microbial
translocation has also been suggested to occur in CVID.[23] Two
case report studies have shown an increase in gd T cells in 1
CVID patient each[24,25]; however, no gd T cells study has been
performed on a larger cohort of CVID patients. We hypothesized that chronic immune activation in CVID patients would
lead to perturbations in gd T cells populations. Thus, we
evaluated the frequency and phenotype of gd T cells in a cohort
of CVID patients.

2.3. Statistical analysis
All statistical analyses were performed using Graph Pad Prism
version 6.0f for Mac OSX (GraphPad Software, La Jolla, CA).
The comparison between healthy controls and CVID patients
was analyzed using Mann–Whitney U test and changes after IVIg
initiation in CVID patients were analyzed with Wilcoxon
matched-pairs signed rank test. Nonparametric analyses were
performed because the data were not normally distributed.
Associations between groups were determined by Spearman
rank correlation. P values <0.05 were considered statistically
signiﬁcant.

2. Materials and methods
3. Results

2.1. Study cohort and samples

3.1. Expansion of Vd1+ and loss of Vd2+ in CVID

Fifteen CVID patients (10 females and 5 males aged 6–51,
average 34) from the Primary Immunodeﬁciency Outpatient
Clinic of Clinical Immunology and Allergy Division of HCFMUSP, fulﬁlling the PAGID/ESID criteria (1999) for CVID
diagnosis and 22 healthy controls (14 females, 8 males aged
25–45, average 36) were enrolled in the study. Group size was
based on sample availability. All patients were HIV negative. The
study was approved by the Hospital das Clínicas, University of
São Paulo Medical School Ethics Committee (CAPPesq), and
written informed consent was provided by all participants or
their legal guardians. Peripheral blood mononuclear cells
(PBMC) were isolated by density-gradient sedimentation using
Ficoll-Paque (Lymphoprep; Nycomed Pharma, Oslo, Norway).
Isolated PBMC were washed twice in Hank balanced salt solution
(Gibco, Grand Island, NY), and cryopreserved in RPMI 1640
(Gibco), supplemented with 20% heat inactivated fetal bovine
serum (FBS; Hyclone Laboratories, Logan, UT), 50 U/mL of
penicillin (Gibco), 50 mg/mL of streptomycin (Gibco), 10 mM
glutamine (Gibco) and 7.5% dimethylsulphoxide (DMSO;
Sigma, St Louis, MO). Cryopreserved PBMC from all subjects
were stored in liquid nitrogen until used in the assays. For CVID
patients, samples were collected before and after initiation of IVIg
treatment.

Table 1 shows the demographic details of the subjects included in
this study. We used cryopreserved PBMCs samples from a
treatment naive cohort of CVID patients followed 9 to 15 months
after initiation of monthly intravenous immunoglobulin replacement therapy (400–600 mg/k) to study gd T cells by ﬂow
cytometry. The viability of the thawed PBMC was over 95% and
there was no difference in the viability between the groups. First,
we evaluated the frequency of the Vd1+, Vd2+, and Vd1 Vd2
gd+ subsets in healthy controls and in treatment naive CVID
patients. In healthy controls, Vd1+ cells typically represented less
than 1% of the T cells and Vd2+ represented the major subset of
gd T cells (Supplementary ﬁle 1, http://links.lww.com/MD/B140).
Supplementary ﬁle 2, http://links.lww.com/MD/B141 summarized all comparisons between CVID patients and healthy
controls. In CVID patients Vd1+ were signiﬁcantly increased
(median 0.60% vs 2.64%, P <0.01) while Vd2+ were reduced
(median, 2.36% vs 0.74%, P <0.01) compared with healthy
controls (Fig. 1A). The frequency of the Vd1 Vd2 gd+ subsets
was also increased in CVID patients (Fig. 1A, median 0.39% vs
0.59%, P <0.05). Overall, this led to a signiﬁcant increase in the
ratio of Vd1+ to Vd2+ (Fig. 1B, 0.24 vs 1.4, P <0.001).
Importantly, the frequency of all subsets of gd T cells was not
changed after IgG replacement therapy (median 2.64% vs
5.25%, P = 0.17; 0.74% vs 1.33% P = 0.58; 0.59% vs 0.60%,
P = 0.21 for Vd1+, Vd2+, and Vd1 Vd2 gd+ T cell respectively).
Next, we compared the absolute count of each subset of gd T
cells in CVID patients to those observed in healthy controls.
Again, Vd1+ were increased (median 7.5 vs 39, P <0.01) and
Vd2+ were decreased (median 37.8 vs 13.9, P <0.01; Fig. 1B).
However, the absolute count of Vd1 Vd2 gd+ was normal in

2.2. Flow cytometry and mAbs
Cryopreserved specimens were thawed, washed, and counts and
viability were assessed using the Countless Automated Cell
Counter system (Invitrogen, Carlsbad, CA). PBMC were washed
and stained in Brilliant Violet Stain Buffer (BD Biosciences, San
Jose, CA) at room temperature for 15 min in 96-well V-bottom
2
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Table 1
Subjects demographics.
CVID 1
CVID 2
CVID 3
CVID 4
CVID 5
CVID 6
CVID 7
CVID 8
CVID 9
CVID 10
CVID 11
CVID 12
CVID 13
CVID 14
CVID 15
CTRL 1
CTRL 2
CTRL 3
CTRL 4
CTRL 5
CTRL 6
CTRL 7
CTRL 8
CTRL 9
CTRL 10
CTRL 11
CTRL 12
CTRL 13
CTRL 14
CTRL 15
CTRL 16
CTRL 17
CTRL 18
CTRL 19
CTRL 20
CTRL 21
CTRL 22

Gender

Age

CD3 (cell/mL)

IgG (mg/mL)

IgA (mg/mL)

IgM (mg/mL)

M
F
M
F
F
F
F
F
M
F
F
M
F
F
M
M
F
M
M
M
F
F
F
F
F
M
F
F
F
F
M
F
M
M
F
F
F

32
27
24
25
31
31
6
31
41
40
34
34
51
35
62
28
25
36
36
30
41
28
31
33
38
59
63
64
17
35
45
25
21
37
33
33
30

1118
1028
2373
1172
1523
2184
NA
1843
2480
2985
1092
1148
1077
2623
781
911
1678
NA
2226
1991
2003
1695
877
1407
1912
1652
1932
1254
1763
1712
NA
NA
4420
4938
1875
1428
1330

63
NA
2
440
273
59
NA
<300
<300
<300
<300
98
86
79
69
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

<25
NA
3.7
2.8
0.6
<25
NA
<50
<50
<50
<50
<50
4
<50
<50
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

<12.5
NA
0.7
3.4
63.8
167.7
NA
<25
<25
<25
33.1
<25
4
25.9
<25
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

CVID patients (median 7.3 vs 9.5, P = 0.69; Fig. 1B). The
absolute count of all subsets of gd T cells was not affected by IVIg
(median, 39 vs 78.3 P = 0.81; 13.9 vs 23.9, P = 0.58; 9.5 vs 7.9
P = 0.69 for Vd1+, Vd2+, and Vd1 Vd2 gd+ T cell respectively).
Thus, our results suggest a speciﬁc expansion of Vd1+ and loss of
Vd2+ subsets in CVID.

cells was not changed after IVIg. Thus, our results show that gd T
cells subsets in CVID have differential distribution of CD4 and
CD8 expression.
3.3. High levels of gd T cells activation in CVID
CVID is characterized by elevated CD4+ and CD8+ T cell
activation,[6] therefore, we hypothesized that gd T cells also had
high levels of activation. We observed elevated levels of CD38,
HLA-DR and coexpression of CD38 and HLA-DR on Vd1+
(median MFI 576 vs 965, P < 0.001; 44.9% vs 73.1%, P <0.01;
30.5% vs 50.3%, P <0.001 respectively), Vd2+ (median MFI
99.1 vs 299, P <0.01; 18.1% vs 44.9%, P <0.01; 8.41% vs
17.2%, P <0.001 respectively), and Vd1 Vd2 gd+ T cells
(median MFI 652 vs 968, P <0.01; 43.7% vs 65.6%, P <0.01;
26.1% vs 49%, P <0.001 respectively, Fig. 3A–C) conﬁrming
our hypothesis. Following replacement therapy CD38 levels and
CD38 and HLA-DR coexpression were reduced only on Vd1+
(median MFI 965 vs 736, P <0.001; 50.3% vs 38.3%, P <0.05
respectively; Fig. 3A and C) but remained higher compared with
healthy controls (median MFI 576 vs 736, P <0.05; 30.5% vs
38.3%, P <0.05 respectively).

3.2. Differential redistribution of CD4+ and CD8+ on gd T
cells in CVID
We evaluated the distribution of CD4 and CD8 expression on gd
T cells for each of the gd T cells subsets individually. As expected,
the major population for all subsets of gd T cells was double
negative (DN). CD4 expression was reduced for Vd1+ and Vd1
Vd2 gd+ T cells in CVID (median 11.6% vs 1.74%, P <0.01;
27.5% vs 8.04%, P <0.001 respectively; Fig. 2A). Vd1+
presented an increased DN population while the CD8 population
was increased for Vd1 Vd2 gd+ (median 45.5% vs 64.4%, P <
0.01; 29.6% vs 32.4%, P <0.05; Fig. 2B and C). On the other
hand, CD4 and CD8 expression was normal on Vd2+ cells
(median 2.62% vs 3.12%, P = 0.96; 29.6% vs 32.4%, P = 0.4
respectively). Expression of CD4 and CD8 on all subsets of gd T
3
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Figure 1. Inverted Vd1+/ Vd2+ ratio in CVID. Frequency of Vd1+, Vd2+, Vd1 Vd2 gd+ T cells
(A), Vd1+/ Vd2+ ratio (B), and absolute count of Vd1+, Vd2+, and Vd1
∗
Vd2 gd+ T cells (C) in healthy controls, treatment naive, and IVIg-treated CVID patients. indicates P <0.05, the lines and whiskers represent the median and
interquartile range respectively. CVID = common variable immunod, IVIg = intravenous immunoglobulin.

3.4. Elevated PD-1 expression by Vd2+ T cells in CVID

4. Discussion

Programmed death 1 (PD-1) is an inhibitory receptor and its
expression is associated with immune exhaustion in chronic
infections.[26] We have previously reported that PD-1 expression is elevated on CD4+ T cells in CVID.[6] Thus, we
investigated PD-1 expression by gd+ T cells in CVID.
We observed that PD-1 expression was normal on Vd1+ and
Vd1 Vd2 gd+ T cells (median, 33.0% vs 43.0%, P = 0.22;
33.9% vs 32.7%, P = 0.88 respectively) but elevated on Vd2+
(median 1.15% vs 3.08%, P <0.001; Fig. 4A). PD-1 remained
elevated on Vd2+ after immune reconstitution (median 1.15%
vs 3.09%, P <0.001) but was reduced on Vd1+ (median 43.0%
vs 36.5%, P <0.05).

Previous case reports described an expansion of gd T cells in 2
CVID patients and this expansion was associated with
Mycobacterium infection for one of them.[24,25] Our ﬁndings
now suggest that perturbations in gd T cells are a general feature
of CVID patients. We observed an increase of Vd1+ and a
decrease of Vd2+ gd T cells in CVID, leading to an inversion of the
Vd1+ to Vd2+ gd T cell ratio. Interestingly, the majority of
sulfatide reactive type II NKT cells have been described to express
Vd1,[27] however it remains to be determined if this population of
type II NKT cells is expanded in CVID patients together with
Vd1+ gd T cells or reduced like type I NKT cells.[28,29]
Vd2+ gd T cells are known to interact with many immune cells
to shape immune responses, including B cells to stimulate
humoral immunity[30] and activated Vd2+ gd T cells have been
shown to act has antigen-presenting cells.[31,32] Furthermore,
Vd2+ T cells can recognize mevalonate metabolites in tumor cells
and are believed to have an important antitumor activity.[33]
Therefore, loss of this cell population could partially explain
some of the immunological perturbation seen in CVID and the
increased incidence of some forms of cancer. More studies are
required to determine if the reduced frequency of Vd2+ gd T cells
in the blood of CVID patients is due to redistribution to tissues or
to a complete loss of those cells. More studies are also needed to
evaluate the functionality of the remaining Vd2+ gd T cells. A
mutation in Vav1 has been associated with impaired Th2

3.5. Activation and exhaustion are associated with gd T
cells frequency in CVID
Finally, we investigated if the elevated levels of activation and
exhaustion could be associated with the change in gd T cells
frequency that we observed. HLA-DR expression was positively
associated with the frequency of Vd1+ and Vd1 Vd2 gd+ T cells
(r = 0.73, P = 0.003; r = 0.68, P = 0.006 respectively; Fig. 5A and
B) but not with Vd2+ T cell frequency (r = 0.022, P = 0.94;
Fig. 5C) in treatment naive CVID patients. Vd2+ T cell frequency
was negatively associated with PD-1 expression (r = 0.67,
P = 0.007; Fig. 5D).
4
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Figure 3. Elevated gd T cells activation in CVID. CD38 MFI (A), levels of HLA-DR
(B), and coexpression of CD38 and HLA-DR (C) ∗by gd+ T cells in healthy controls,
treatment naive, and IVIg-treated CVID patients. indicates P <0.05, the lines and
whiskers represent the median and interquartile range respectively.

Figure 2. Altered CD4 and CD8 expression on gd T cells in CVID. Proportion of
gd+ T cells expressing CD4 (A), CD8 (B), or∗DN (C) in healthy controls, treatment
naive, and IVIg-treated CVID patients. indicates P <0.05, the lines and
whiskers represent the median and interquartile range respectively.

response in a subset of CVID patients,[34,35] more experiments
are needed to assess the impact of this mutation on gd T cell
functionality.
The high levels of activation of all subsets of gd T cells that we
report here were not affected by IVIg treatment, suggesting that
IVIg is not controlling the factors responsible for gd T cells
activation. However, it is possible that a longer period of time on
replacement therapy is needed to observe a reduction in gd T cells
activation. There is now accumulating evidence that IgG
replacement does not restore a normal immune system in CVID.
Complementary therapies aiming to restore normal cellular
immunity should be considered and could prevent some of the
complications associated with CVID. Long-term low-dose IL-2
has been shown to enhance T cell function in CVID patients[36]
but other compartments of the cellular immune system were not
studied.
Interestingly, the expansion of Vd1+ and the reduction in Vd2+
gd T cells in CVID is similar to that which has been described for

Figure 4. Expression of PD-1 by gd T cells in CVID. Levels of PD-1 expression
by gd+ T ∗cells (A) in healthy controls, treatment naive, and IVIg-treated CVID
patients. indicates P <0.05, the lines and whiskers represent the median and
interquartile range respectively. PD-1 = Programmed Death 1.
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Figure 5. Associations between activation, exhaustion, and gd T cells subsets frequency in CVID. Correlation between HLA-DR expression and Vd1+ (A), Vd1
Vd2 gd+ (B), Vd2+ (C) T cells frequency in treatment naive CVID patients. Correlation between PD-1 expression and Vd2+ T cells frequency in treatment naive CVID
patients (D).

HIV infection,[16] suggesting that common drivers in the
pathology associated with primary and secondary immunodeﬁciency might exist. In this regard, microbial translocation has
been implicated in the inversion of the Vd1+ to Vd2+ ratio in SIV
infection[19] and in CD4 T cell exhaustion in CVID.[23]
Expansion of Vd1+ and Vd1 Vd2 gd+ T cells in CVID was
associated with activation, suggesting an implication for chronic
inﬂammation in expending those subsets of gd T cells. Therefore,
we propose that inversion of the Vd1 to Vd2 ratio in CVID is a
reﬂection of the infection burden.
Altogether, our results suggest that IVIg replacement therapy is
not sufﬁcient to normalize change in gd T cells frequency and
activation in CVID. Furthermore, our results add to the list of
similarities between primary and secondary immunodeﬁciencies,
such as HIV infection.

[3] Cunningham-Rundles C, Bodian C. Common variable immunodeﬁciency: clinical and immunological features of 248 patients. Clin Immunol
1999;92:34–48.
[4] Resnick ES, Moshier EL, Godbold JH, et al. Morbidity and mortality in
common variable immune deﬁciency over 4 decades. Blood 2012;119:
1650–7.
[5] Paquin-Proulx D, Sandberg JK. Persistent immune activation in CVID
and the role of IVIg in its suppression. Front Immunol 2014;5:637.
[6] Paquin-Proulx D, Santos BA, Carvalho KI, et al. IVIg immune
reconstitution treatment alleviates the state of persistent immune
activation and suppressed CD4 T cell counts in CVID. PLoS One
2013;8:e75199.
[7] Vlkova M, Ticha O, Nechvatalova J, et al. Regulatory B cells in
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